KRAS and lung carcinoma: Unlike patients with lung cancer harboring EGFR mutations or ALK translocations, diseases for which targeted agents typically achieve 60 to 80% response rates, KRAS G12C inhibitors such as sotorasib and adagrasib typically yield 40 to 50% response rates [8].